Physician profile

Ansley Brown

Pediatrics (Nurse Practitioner) · San Antonio, TX

NPI 1902232861

$882.71

in general payments reported to CMS, 2019-2025

7 companies · $8.46 in 2025

See the full distribution for Pediatrics (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$499.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $295.35 2021-2023 Shingrix, Arexvy
Regeneron Healthcare Solutions, INC. $124.99 2021
Astrazeneca Pharmaceuticals LP $124.27 2023 Fasenra
Genzyme Corporation $121.61 2024
Pharming Healthcare, INC. $120.61 2024
Seqirus USA INC $87.42 2023
Evofem Biosciences, INC. $8.46 2025 Solosec, Phexx, Phexxi

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ansley Brown

$882.71

in general payments reported 2019-2025

Years
2021-2025
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/10491505/ansley-brown

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.